RT Journal
A1 Katz MH
T1 Zonisamide: Comment on “zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial”
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2012
FD November 12
VO 172
IS 20
SP 1565
OP 1565
DO 10.1001/2013.jamainternmed.108
UL http://dx.doi.org/10.1001/2013.jamainternmed.108
AB 
Zonisamide at a daily dose of 400 mg, combined with diet and lifestyle counseling, provided moderately successful weight loss in this trial (7.3 kg [3.3 kg more than placebo] at 1 year) as it did in prior trials. The problem is that the adverse effects at this dose are substantial: 18.7% of patients experienced headache, 13.3% experienced nausea/vomiting, 9.3% experienced anxiety, and 10.7% experienced impaired memory.